GRALNasdaqServices-Medical LaboratoriesFiscal year ends December 31
GRAIL, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$122.42+4.61 (+3.91%)
Close on Oct 19, 2026
- Market cap
- $5.28B
- P/E (TTM)
- –
- Dividend yield
- –
GRAIL, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Screening revenue | $138.60M | $108.63M | $75.00M | $39.82M | 94.2% | +27.6% |
| Development Services | $8.57M | $16.97M | $18.11M | $15.73M | 5.8% | -49.5% |
By region
From the segment and revenue-disaggregation notes of Grail's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.